Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant

Hepatology

Volumn 61, Issue 6, 2015, Pages 1880-1886

  Pungpapong, Surakit ^a   Aqel, Bashar ^b   Leise, Michael ^c   Werner, K Tuesday ^b   Murphy, Jennifer L ^a   Henry, Tanisha M ^a   Ryland, Kristen ^a   Chervenak, Amy E ^b   Watt, Kymberly D ^c   Vargas, Hugo E ^b   Keaveny, Andrew P ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSPORIN; HEMOGLOBIN; MYCOPHENOLATE MOFETIL; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; PREDNISONE; RAPAMYCIN; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TRIACYLGLYCEROL LIPASE; VIRUS RNA; ANTIVIRUS AGENT; FUSED HETEROCYCLIC RINGS; SULFONAMIDE; URIDINE PHOSPHATE;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ACUTE PANCREATITIS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTASIS; CHRONOTHERAPY; COUGHING; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EPIGASTRIC PAIN; EXPERIENCE; FATIGUE; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HUMAN TISSUE; HYPERVOLEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; INTERVENTION STUDY; LIVER TRANSPLANTATION; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PHOTOSENSITIVITY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RECURRENT DISEASE; SKIN MANIFESTATION; SUSTAINED VIROLOGIC RESPONSE; TIME TO TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URETER STONE; VIRAL PHENOMENA AND FUNCTIONS; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; GENETICS; GENOTYPE; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDY;

AGED; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; RIBAVIRIN; SULFONAMIDES; TREATMENT OUTCOME; URIDINE MONOPHOSPHATE;

EID: 84929582082     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27770     Document Type: Article

References (26)

1. OPTN/SRTR 2012 annual data report: liver. Rockville, MD: Health Resources and Services Administration, Available at: http://srtr.transplant.hrsa.gov/annual_reports/2012/pdf/03_liver_13.pdf.
2. Biggins SW, Bambha KM, Terrault NA, Inadomi J, Shiboski S, Dodge JL, et al. Projected future increase in aging hepatitis C virus-infected liver transplant candidates: a potential effect of hepatocellular carcinoma. Liver Transpl 2012;18:1471-1478.
3. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012;142:1373-1383.
4. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-684.
5. Carrión JA, Navasa M, García-Retortillo M, García-Pagan JC, Crespo G, Bruguera M, et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology 2007:132:1746-1756.
6. Berenguer M, Palau A, Aguilera V, Rayón JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008;8:679-687.
7. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006;6:1586-1599.
8. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013:58:1028-1041.
9. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, et al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013;19:690-700.
10. Burton JR Jr, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. J Hepatol 2014:61:508-514.
11. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014;60:78-86.
12. Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, et al. Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience. Ann Hepatol 2014:13:525-532.
13. Kwo PY, Ghabril M, Lacerda MA, Joseph Tector A, Fridell JA, Vianna R. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post-orthotopic liver transplant. Clin Transplant 2014:28:722-727.
14. Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corrigidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naïve patients: the COSMOS randomised study. Lancet 2014;384(9956):1756-1765.
15. American Association for the Study of Liver Diseases, Infectious Diseases Society of America, International Antiviral Society-USA. Recommendations for Testing, Managing, and Treating Hepatitis C. Available at: http://www.hcvguidelines.org. Accessed January 5, 2015.
16. EASL. Recommendations on Treatment of Hepatitis C. 2014. Available at: http://www.easl.eu/assets/application/files/easl_recommendations_hcv_2014_full.pdf.
17. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994;20:15-20.
18. Ouwerkerk-Mahadevan S, Simion A, Mortier S, Peeters M, Beumont M. No clinically significant interaction between the investigational HCV protease inhibitor simeprevir (TMC435) and the immunosuppressive agents cyclosporine and tacrolimus [Abstract]. Hepatology 2012;56(Suppl. 1):231A.
19. Olysio (simeprevir) prescribing information. Titusville, NJ: Janssen, Inc.; 2014.
20. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2014;148(1):108-117.
21. Kwo PY, Mantry PS, Coakley E, Te HS, Vargas HE, Brown R, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med 2014;371(25):2375-2382.
22. Reddy KR, Everson GT, Flamm SL, Denning JM, Arterburn S, Brandt-Sarif T, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study [Abstract]. Hepatology 2014;60(Suppl. 1):200A-201A.
23. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014;384(9941):403-413.
24. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014;384(9941):414-426.
25. Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014;146(7):669-679.
26. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir increases rate of sustained virologic response among treatment-experiences patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology 2014;146(2):430-441.